Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials

A three-pronged acne treatment approach —combining an antibiotic, antibacterial agent, and retinoid—may provide greater efficacy than single/double treatments. Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (IDP-126) is the first fixed-dose triple-combination in development for acne.

Source: Journal of the American Academy of Dermatology - September 1, 2023 Category: Dermatology Authors: Linda Stein Gold, Edward Lain, James Q. Del Rosso, Michael Gold, Zoe D. Draelos, Lawrence F. Eichenfield, Neil Sadick, William P. Werschler, Melinda J. Gooderham, Mary Lupo Tags: Original article Source Type: research